Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency

NCT02604810 is registered in ClinicalTrials.gov with Grifols Therapeutics LLC as lead sponsor.

NCT NCT02604810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02604810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency
Lead sponsor
Grifols Therapeutics LLC
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2016
Completion date
December 31, 2017
Enrollment
53 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

primary immunodeficiency